Aspire Biopharma Holdings, INC. (ASBPW) SEC Filings — 2025

Filings

• Aspire Biopharma Files S-1 for 41.5M Share Resale, Eyes $100M ELOC Funding — S-1 · Dec 3, 2025
• Aspire Biopharma's Net Loss Explodes to $19.8M Amidst Reverse Acquisition — 10-Q/A · Nov 14, 2025
• Aspire Biopharma Holdings Files 8-K on Shareholder Vote — 8-K · Nov 5, 2025
• Aspire Biopharma Faces Delisting Notice — 8-K · Oct 17, 2025
• Aspire Biopharma Files 8-K: Equity Sales & Accountant Change — 8-K · Sep 26, 2025
• Aspire Biopharma Seeks Reverse Split, Note Conversion Approval — DEF 14A · Sep 23, 2025
• Aspire Biopharma Registers 147M Shares for Resale, Seeks Reverse Split Nod — S-1 · Sep 18, 2025
• Aspire Biopharma Files 8-K for Material Agreement — 8-K · Aug 22, 2025
• Aspire Biopharma Restates Q1, Reveals $1M Liability Error — 10-Q/A · Aug 13, 2025
• Aspire Biopharma Announces Board and Compensation Changes — 8-K · Jul 30, 2025
• Aspire Biopharma Files 8-K, Formerly PowerUp Acquisition Corp. — 8-K · Jun 18, 2025
• Aspire Biopharma Files 8-K: Director Changes & Officer Appointments — 8-K · Jun 10, 2025
• Aspire Biopharma Files Q1 2025 10-Q — 10-Q · May 14, 2025
• Aspire Biopharma Files S-1 for Public Offering — S-1 · May 13, 2025
• Aspire Biopharma Enters Material Definitive Agreement — 8-K · Apr 30, 2025
• Aspire Biopharma Faces Delisting Notice — 8-K · Apr 18, 2025
• Aspire Biopharma Files S-1 for Securities Registration — S-1 · Apr 9, 2025
• Aspire Biopharma Files 2024 10-K — 10-K · Apr 7, 2025
• Aspire Biopharma Holdings, Inc. Files 8-K with Multiple Material Events — 8-K · Feb 21, 2025
• Aspire Biopharma Announces Material Agreement & Equity Sales — 8-K · Feb 20, 2025
• PowerUp Acquisition Corp. Files 8-K on Shareholder Vote and Financials — 8-K · Feb 10, 2025